DJ MARKET TALK: GSK's Tykerb Gets Strong FDA Endorsement

11/16/06 - Dow Jones Newswires

1308 GMT [Dow Jones] GlaxoSmithKline (GSK) +0.2% at 1366p after FDA grants priority review to breast cancer drug Tykerb. Collins Stewart analyst Navid Malik says the endorsement is strong and shows the regulator considers Tykerb a pivotal product in the cancer market. Expects a successful review for the drug, meaning that it could be on the market in six months. Forecasts peak sales of $2B. Keeps buy recommendation with 2307p target price. (EXB)

 
Contact us in London. +44-20-7842-9464 
Markettalk.eu@dowjones.com 
 
 

(END) Dow Jones Newswires

November 16, 2006 08:08 ET (13:08 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc.